All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold

Evaluation of ColdZyme Mouth Spray against Common Cold in Elderly Care Personnel

User Experience of ColdZyme Mouth Spray against Common Cold in Competitive Athletes

Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff

Evaluation of ColdZyme Mouth Spray for the Protection against Common Cold in Elite Athletes to Reduce Unwanted Absence from Training and Competition

Trichloroacetic Acid Spray for the Treatment of Foot Ulcers of Foot and Mouth Disease in Cattle

THE IMPORTANCE OF DOMINANT HAND AT PLACEBO EFFECT OF INERT SPRAY TO MUSCULAR FATIGUE INDUCED EXPERIMENTALLY

Vapocoolant Spray vs Lidocaine/Prilocaine Cream for Reducing the Pain of Venipuncture in Hemodialysis Patients: A Randomized, Placebo-Controlled, Crossover Study

A double blind, randomised placebo controlled trial of topical 2% viscous lidocaine in improving oral intake in children with painful infectious mouth conditions

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Ranging Multicenter Study to Determine the Effect of Sublingual Nitroglycerin Spray on Exercise Capacity in Patients with Chronic Stable Angina

Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold

More...

A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold

DOI: 10.4236/ojrd.2017.74013, PP. 125-135

Keywords: Common Cold, Rhinovirus, ColdZyme?® Mouth Spray

Full-Text   Cite this paper   Add to My Lib

Abstract:

Common colds incur significant costs in terms of sick leave and personal discomfort for affected individuals. This study investigated the performance of ColdZyme Mouth Spray (ColdZyme), a protective barrier against common cold, in rhinovirus-inoculated healthy volunteers. This randomized, doubleblind, placebo-controlled pilot study was conducted on 46 healthy volunteers inoculated with rhinovirus 16 via the nose. Subjects self-administered ColdZyme or placebo 6 times daily for 11 days. Symptoms were recorded daily in a diary. Rhinovirus 16 in nasal and oropharyngeal samples at days 0, 3, 4, 6, 7 and 10 were quantified by RT-qPCR. The primary outcome measure was the reduction in viral load in oropharyngeal samples. Rhinovirus 16 was only detected in 35 out of 46 inoculated subjects. Exploratory analysis measuring the total viral load (i.e., area under the curve (AUC)) for days 3 - 10 in successfully inoculated subjects found that ColdZyme treatment resulted in a lower total viral load in the oropharynx (p = 0.023). In subjects who experienced symptomatic common cold, irrespectively, if virus were detected, treatment with ColdZyme resulted in a reduction in the number of days with common cold symptoms from 6.5 to 3.0 days (p = 0.014) in comparison to placebo. ColdZyme reduced virus infection in the oropharynx and reduced the number of days with common cold symptoms and highlights the possible importance of the oropharynx in common cold infections. Suitable outcome measures for a feasible study on ColdZyme are total viral load in the oropharynx in subjects having detectable virus present in nasal or oropharyngeal samples.

References

[1]  Johnston, S.L., Pattemore, P.K., Sanderson, G., Smith, S., Lampe, F., Josephs, L., Symington, P., O’Toole, S., Myint, S.H., Tyrrell, D.A.J. and Holgate, S.T. (1995) Community Study of Role of Viral Infections in Exacerbations of Asthma in 9-11 Year Old Children. BMJ, 310, 1225-1229.
https://doi.org/10.1136/bmj.310.6989.1225
[2]  Bramley, T.J., Lerner, D. and Sarnes, M. (2002) Productivity Losses Related to the Common Cold. Journal of Occupational and Environmental Medicine, 44, 822-829.
https://doi.org/10.1097/00043764-200209000-00004
[3]  Arruda, E., Pitkaranta, A., Witek, T.J., Doyle, C.A. and Hayden, F.G. (1997) Frequency and Natural History of Rhinovirus Infections in Adults during Autumn. Journal of Clinical Microbiology, 35, 2864-2868.
[4]  Heikkinen, T. and Järvinen, A. (2003) The Common Cold. The Lancet, 361, 51-59.
https://doi.org/10.1016/S0140-6736(03)12162-9
[5]  Vareille, M., Kieninger, E. and Edwards, M.R. (2011) The Airway Epithelium: Soldier in the Fight against Respiratory Viruses. Clinical Microbiology Reviews, 24, 210-229.
https://doi.org/10.1128/CMR.00014-10
[6]  Hayden, F.G., Turner, R.B., Gwaltney, J.M., Chi-Burris, K., Gersten, M., Hsyu, P., Patick, A.K., Smith, G.J. and Zalman, L.S. (2003) Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 47, 3907-3916.
https://doi.org/10.1128/AAC.47.12.3907-3916.2003
[7]  Bardin, P.G., Sanderson, G., Robinson, B.S., Holgate, S.T. and Tyrrell, D.A. (1996) Experimental Rhinovirus Infection in Volunteers. The European Respiratory Journal, 9, 2250-2255.
https://doi.org/10.1183/09031936.96.09112250
[8]  Jackson, G.G., Dowling, H.F., Spiesman, I.G. and Boand A.V. (1958) Transmission of the Common Cold to Volunteers under Controlled Conditions. I. The Common Cold as a Clinical Entity. A.M.A. Archives of Internal Medicine, 101, 267-278.
https://doi.org/10.1001/archinte.1958.00260140099015
[9]  Greiff, L., Andersson, M. and Persson, C.G.A. (2001) Nasal Secretions and Exudations: Collection and Approaches to Analysis. In: Rogers, D.F. and Donnelly, L.E., Eds., Methods in Molecular Medicine, Humana Press, Totowa, 56, 61-73.
[10]  Gwaltney, J.M., Hendley, J.O. and Patrie, J.T. (2003) Symptom Severity Patterns in Experimental Common Colds and Their Usefulness in Timing Onset of Illness in Natural Colds. Clinical Infectious Diseases, 36, 714-723.
https://doi.org/10.1086/367844
[11]  Jones, R.M. and Su, Y.M. (2015) Dose-Response Models for Selected Respiratory Infectious Agents: Bordetella pertussis, Group a Streptococcus rhinovirus and Respiratory Syncytial Virus. BMC Infectious Diseases, 15, 90.
https://doi.org/10.1186/s12879-015-0832-0
[12]  Kennedy, J.L., Turner, R.B., Braciale, T., Heymann, P.W. and Borish, L. (2012) Pathogenesis of Rhinovirus Infection. Current Opinion in Virology, 2, 287-293.
https://doi.org/10.1016/j.coviro.2012.03.008
[13]  Dhariwal, J., Edwards, M.R. and Johnston, S.L. (2013) Anti-Viral Agents: Potential Utility in Exacerbations of Asthma. Current Opinion in Pharmacology, 13, 331-336.
https://doi.org/10.1016/j.coph.2013.04.010
[14]  Dimopoulos, G., Lerikou, M., Tsiodras, S., Chranioti, A., Perros, E., Anagnostopoulou, U., Armaganidis, A. and Karakitsos P. (2012) Viral Epidemiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Pulmonary Pharmacology & Therapeutics, 25, 12-18.
https://doi.org/10.1016/j.pupt.2011.08.004
[15]  Pavia, A.T. (2011) Viral Infections of the Lower Respiratory Tract: Old Viruses, New Viruses, and the Role of Diagnosis. Clinical Infectious Diseases, 52, 284-289.
https://doi.org/10.1093/cid/cir043
[16]  Papadopoulos, N.G., Bates, P.J., Bardin, P.G., Papi, A., Leir, S.H., Fraenkel, D.J., Meyer, J., Lackie, P.M., Sanderson, G., Holgate, S.T. and Johnston, S.L. (2000) Rhinoviruses Infect the Lower Airways. The Journal of Infectious Diseases, 181, 1875-1884.
https://doi.org/10.1086/315513

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal